First New York Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

First New York Securities’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1	Closed	-$156	–	293
2015 Q3	$156	Hold	1	–	–	﹤0.01%	328
2015 Q2	$181	Buy	+1	New	+$173	﹤0.01%	420
2013 Q4	–	Sell	-1,500	Closed	-$174K	–	410
2013 Q3	$174K	Buy	+1,500	New	+$165K	0.07%	190

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First New York Securities's ALXN Position: Q4 2015 in Review

First New York Securities sold out of Alexion Pharmaceuticals (ALXN) in Q4 2015, closing a stake of 1 share — an estimated $156 sold.

First New York Securities first reported a position in ALXN in Q3 2013 and held it in 3 quarters. The position peaked at $174K in Q3 2013. 547 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

First New York Securities reported no remaining Alexion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
First New York Securities sold 1 Alexion Pharmaceuticals share in Q4 2015, an estimated $156.
First New York Securities first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 3 quarters.
First New York Securities's Alexion Pharmaceuticals position peaked at $174K in Q3 2013.
547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on First New York Securities's 13F filing for Q4 2015, filed 25 Jan 2016.